To investigate this, we examined whether NRF2 deletion promotes IPMN formation by altering global ROS levels, following established protocols to perturb intrapancreatic ROS (15). The gene discussed is NFE2L2; the disease is pancreatic intraductal papillary-mucinous neoplasm.